New cancer drug combo tested in Final-Stage trial for Tough-to-Treat colorectal cancer
NCT ID NCT05600309
Summary
This completed Phase 3 trial tested whether a new two-in-one immunotherapy drug (MK-4280A) works better than standard chemotherapy for Chinese adults with advanced colorectal cancer that had spread and stopped responding to prior treatments. The main goal was to see if the new treatment helped patients live longer. Researchers compared the new drug against two standard oral chemotherapy medications (regorafenib and TAS-102).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 1185)
Wuxi, Jiangsu, 214122, China
-
Changzhou Cancer Hospital-Department of Oncology ( Site 1183)
Changzhou, Jiangsu, 213000, China
-
Chongqing Cancer Hospital ( Site 1151)
Chongqing, Chongqing Municipality, 400030, China
-
Fudan University Shanghai Cancer Center ( Site 1176)
Shanghai, Shanghai Municipality, 201321, China
-
Fujian Province Cancer Hospital ( Site 1178)
Fuzhou, Fujian, 350014, China
-
Guangxi Medical University Affiliated Tumor Hospital ( Site 1158)
Nanning, Guangxi, 531021, China
-
Hainan General Hospital ( Site 1177)
Haikou, Hainan, 570311, China
-
Hubei Cancer Hospital ( Site 1152)
Wuhan, Hubei, 430079, China
-
Hunan Cancer Hospital ( Site 1174)
Changsha, Hunan, 410013, China
-
Jilin Cancer Hospital ( Site 1163)
Changchun, Jilin, 130012, China
-
Jinan Central Hospital ( Site 1167)
Jinan, Shandong, 250000, China
-
Shanghai Tenth People's Hospital ( Site 1170)
Shanghai, Shanghai Municipality, 200072, China
-
Sir Run Run Shaw Hospital-Medical Oncology ( Site 1173)
Hangzhou, Zhejiang, 310018, China
-
Southern Medical University Nanfang Hospital ( Site 1154)
Guangzhou, Guangdong, 510515, China
-
Sun Yat-Sen University Cancer Center ( Site 1150)
Guangzhou, Guangdong, 510060, China
-
The Second Affiliated Hospital of Anhui Medical University ( Site 1179)
Hefei, Anhui, 230601, China
-
The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159)
Guangzhou, Guangdong, 510655, China
-
The Third Xiangya Hospital of Central South University ( Site 1175)
Changsha, Hunan, 410013, China
-
Tianjin Medical University Cancer Institute and Hospital ( Site 1161)
Tianjin, Tianjin Municipality, 300060, China
-
West China Hospital Sichuan University ( Site 1172)
Chengdu, Sichuan, 332001, China
-
Wuhan Union Hospital Cancer Center ( Site 1162)
Wuhan, Hubei, 430022, China
-
Xiangya Hospital Central South University ( Site 1171)
Changsha, Hunan, 410008, China
-
Yunnan Province Cancer Hospital-Colorectal surgery ( Site 1169)
Kunming, Yunnan, 650106, China
-
Zhejiang Cancer Hospital ( Site 1180)
Hangzhou, Zhejiang, 310005, China
Conditions
Explore the condition pages connected to this study.